Want to see DVA full AI Analyst Report?
DVA Stock Chart & Stats
$147.91
$0.74(0.48%)
At close: 4:00 PM EST
$147.91
$0.74(0.48%)
Day’s Range― - ―
52-Week Range$101.00 - $239.64
Previous CloseN/A
Volume85.32K
Average Volume (3M)771.88K
Market Cap
$15.23B
Enterprise Value$24.86K
Total Cash (Recent Filing)$748.71M
Total Debt (Recent Filing)$13.22B
Price to Earnings (P/E)22.7
Beta0.50
Next Earnings
Aug 04, 2026EPS Estimate
3.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.15
Shares Outstanding64,200,000
10 Day Avg. Volume689,212
30 Day Avg. Volume771,885
Financial Highlights & Ratios
PEG Ratio-0.99
Price to Book (P/B)-15.02
Price to Sales (P/S)0.72
P/FCF Ratio7.46
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$231.80Price Target Upside56.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)14.88
Revenue Forecast (FY)$14.09B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationConsistent, multi-billion dollar operating and free cash flow provides durable internal funding for capital expenditures, technology investments, share repurchases and debt servicing. This cash generation supports strategic flexibility and resilience across economic cycles over the next 2–6 months.
Solid Operating Margins And Steady Revenue GrowthSustained low-to-mid single-digit revenue growth combined with double-digit operating margins indicates structural efficiency in clinic operations and pricing power per treatment. Margin durability suggests the business can absorb moderate cost pressures while preserving profitability over the medium term.
Strategic Tech And AI Investments To Boost ProductivityTargeted modernization and AI deployments aim to raise caregiver productivity, optimize scheduling and clinical workflows, and lower unit costs over time. These structural initiatives can deliver sustainable operating leverage and competitive advantage across the clinic network if execution remains on plan.
Bears Say
Very High Leverage And Negative EquityElevated debt and a negative equity position materially constrain financial flexibility, raise refinancing and covenant risks, and increase sensitivity to interest rates and cash flow swings. This balance-sheet structure is a persistent vulnerability that limits strategic optionality in the coming months.
Persistent Interest Expense BurdenHigh recurring interest costs meaningfully reduce free cash flow available for growth or deleveraging. With leverage near the upper end of target and consistent quarterly debt expense, interest payments will remain a durable drag on cash returns and capital-allocation flexibility.
Revenue-per-treatment And Payer-mix Risk (ACA Uncertainty)Reliance on payer mix and reimbursement trends creates structural revenue risk: weaker commercial mix or ACA shifts can erode revenue per treatment and margins. This exposure to payor dynamics and policy-driven enrollment changes can pressure revenue sustainability over the medium term.
DaVita News
DVA FAQ
What was DaVita Inc.’s price range in the past 12 months?
DaVita Inc. lowest stock price was $101.00 and its highest was $239.64 in the past 12 months.
What is DaVita Inc.’s market cap?
DaVita Inc.’s market cap is $15.23B.
When is DaVita Inc.’s upcoming earnings report date?
DaVita Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 12 days.
How were DaVita Inc.’s earnings last quarter?
DaVita Inc. released its earnings results on May 05, 2026. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54.
Is DaVita Inc. overvalued?
According to Wall Street analysts DaVita Inc.’s price is currently Undervalued.
Does DaVita Inc. pay dividends?
DaVita Inc. does not currently pay dividends.
What is DaVita Inc.’s EPS estimate?
DaVita Inc.’s EPS estimate is 3.88.
How many shares outstanding does DaVita Inc. have?
DaVita Inc. has 64,200,000 shares outstanding.
What happened to DaVita Inc.’s price movement after its last earnings report?
DaVita Inc. reported an EPS of $2.87 in its last earnings report, beating expectations of $2.33. Following the earnings report the stock price went up 23.459%.
Which hedge fund is a major shareholder of DaVita Inc.?
Currently, no hedge funds are holding shares in DVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DaVita Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$231.80 (56.72% Upside)
$231.80 (56.72% Upside)
Blogger Sentiment
Bullish
DVA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $33.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.22%
Trailing 12-Months
Company Description
DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
DVA Revenue Breakdown
85.99% U.S. dialysis
14.01% Ancillary services
DVA Stock 12 Month Forecast
Average Price Target
$231.80
▲(56.72% Upside)
Technical Analysis
Fresenius Medical Care
―
HCA Healthcare
―
Encompass Health
―
Tenet Healthcare
―
The Ensign Group
―
Ownership Overview
47.00% Insiders
10.82% Mutual Funds
0.62% Other Institutional Investors
25.90% Public Companies and
Individual Investors